We conducted this study to explore personal accounts of making choices about taking medication prescribed for the treatment of psychosis (neuroleptics). There are costs and benefits associated with continuing and discontinuing neuroleptics. Service users frequently discontinue neuroleptics; therefore, we specifically considered these decisions. We used a grounded theory approach to analyze transcripts from interviews with 12 participants. We present a preliminary grounded theory of the processes involved in making choices about neuroleptic medication. We identified three tasks as important in mediating participants’ choices: (a) forming a personal theory of the need for, and acceptability of taking, neuroleptic medication; (b) negotiating the challenges of forming alliances with others; and (c) weaving a safety net to safeguard well-being. Progress in the tasks reflected a developmental trajectory of becoming an expert over time and was influenced by systemic factors. Our findings highlight the importance of developing resources for staff to facilitate service user choice.
American Psychiatric Association. (2004). Practice Guideline for the Treatment of Patients with Schizophrenia (2nd ed.). American Journal of Psychiatry, 161(Suppl.), 1–56.
2.
CaltonT.FerriterM.HubandN.SpandlerH. (2008). A systematic review of the Soteria Paradigm for the treatment of people diagnosed with schizophrenia. Schizophrenia Bulletin, 34, 181–192.
3.
CharmazK. (2006). Constructing grounded theory: A practical guide through qualitative analysis. London: Sage.
4.
ChenitzW. C.SwansonJ. M. (1986). From practice to grounded theory. Menlo Park, CA: Addison-Wesley.
5.
CooperD.MoisanJ.GaudetM.AbdousB.GregoireJ. P. (2005). Ambulatory use of olanzapine and risperidone: A population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Canadian Journal of Psychiatry, 50, 901–908.
6.
CorbinJ.StraussA. (2008). Basics of qualitative research: Techniques and procedures for developing grounded theory. London: Sage.
7.
CormierE. (2012). How parents make decisions to use medication to treat their child’s ADHD: A Grounded Theory Study. Journal of the American Psychiatric Nurses Association, 18, 345–356.
8.
CoulterA.CollinsA. (2011). Making shared decision-making a reality: No decision about me, without me. London: The King’s Fund.
9.
DartonK. (2013). Making sense of coming off psychiatric drugs. Oakland, CA and London: Mind Publications.
DeeganP. E. (2005). The importance of personal medicine: A qualitative study of resilience in people with psychiatric disabilities. Scandinavian Journal of Public Health, 33, 29–35.
12.
DeeganP. E.DrakeR. E. (2006). Shared decision making and medication management in the recovery process. Psychiatric Services, 57, 1636–1639.
13.
Department of Health. (2001). The expert patient: A new approach to chronic disease management for the 21st century. London: The Stationery Office.
14.
DeyI. (1999). Grounding grounded theory: Guidelines for qualitative inquiry. San Diego, CA: Academic Press.
15.
DolderC. R.LacroJ. P.LeckbandS.JesteD. (2003). Interventions to improve antipsychotic medication adherence: Review of recent literature. Journal of Clinical Psychopharmacology, 23, 389–399.
16.
ElliottR.FischerC. T.RennieD. L. (1999). Evolving guidelines for publication of qualitative research studies in psychology and related fields. British Journal of Clinical Psychology, 38, 215–229.
17.
FakhouryW.WrightD.WallaceM. (2001). Prevalence and extent of adverse effects of antipsychotics among callers to a United Kingdom National Mental health Helpline. International Journal of Clinical Psychopharmacology, 16, 153–162.
GeekieJ. (2013). Listening to the voices we hear: Clients’ understandings of psychotic experiences. In ReadJ.DillonJ. (Eds.), Models of madness: Psychological, social and biological approaches to psychosis (2nd ed., pp. 178–190). London: Routledge.
20.
GilbertP. L.HarrisM. J.McAdamsL. A.JesteD. V. (1995). Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Archives of General Psychiatry, 52, 173–188.
21.
GlaserB. G. (1978). Theoretical sensitivity. Mill Valley, CA: The Sociology Press.
22.
GlaserB. G. (1998). Doing grounded theory: Issues and discussions. Mill Valley, CA: The Sociology Press.
23.
GlaserB. G.StraussA. L. (1967). The discovery of grounded theory: Strategies for qualitative research. Chicago: Aldine.
24.
GoossensenA.ZijlstraP.KoopmanschapM. (2007). Measuring shared decision making processes in psychiatry: Skills versus patient satisfaction. Patient Education & Counseling, 67, 50–56.
25.
GossC.MorettiF.MazziM. A.Del PiccoloL.RimondiniM.ZimmermannC. (2008). Involving patients in decisions during psychiatric consultations. British Journal of Psychiatry, 193, 416–421.
HallW.CalleryP. (2001). Enhancing the rigor of grounded theory: Incorporating reflexivity and relationality. Qualitative Health Research, 11, 257–272.
28.
HarrowM.JobeT. H.FaullR. N. (2012). Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychological Medicine, 42, 2145–2155.
29.
Healthcare Commission. (2007). Talking about medications: The management of medicines in trusts providing mental health services. London: Commission for Healthcare, Audit & Inspection. Available from www.healthcarecommission.org
30.
HillD. (1986). Tardive dyskinesia: A worldwide epidemic of irreversible brain damage. In EisenbergN.GlasgowD. (Eds.), Current issues in clinical psychology. Aldershot, UK: Gower.
31.
HoB. C.AndreasenN. C.ZiebellS.PiersonR.MagnottaV. (2011). Long-term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Archives of General Psychiatry, 68, 128–137.
32.
HogmanG.SandamasG. (2000). A question of choice. London: Rethink Publications.
33.
JacksonL.HaywardM.CookeA. (2011). Developing positive relationships with voices: A preliminary grounded theory. International Journal of Social Psychiatry, 57, 487–495.
34.
JohnstoneL.DallosR. (Eds.). (2006). Formulation in psychology and psychotherapy: Making sense of people’s problems. London: Routledge.
35.
KreyenbuhlJ.SladeE. P.MedoffD. R.BrownC. H.EhrenreichB.AffulJ.DixonL. B. (2011). Time to discontinuation of first-and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophrenia Research, 131, 127–132.
36.
LandierW.HughesC. B.CalvilloE. R.AndersonN. L. R.Briseno-ToomeyD.DominguezL.. . . BhatiaS. (2011). A grounded theory of the process of adherence to oral chemotherapy in Hispanic and Caucasian children and adolescents with acute lymphoblastic leukemia. Journal of Pediatric Oncology Nursing, 28, 203–223.
37.
LehmannP. (2002). Coming off psychiatric drugs: Successful withdrawal from neuroleptics, antidepressants, lithium, carbamazepine and tranquilizers. Berlin: Peter Lehmann.
38.
LeuchtS.ArbterD.EngelR. R.KisslingW.DavisJ. M. (2009). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry, 14, 429–447.
39.
LeuchtS.TardyM.KomossaK.HeresS.KisslingW.SalantiG.DavisJ. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379, 2063–2071.
40.
LiebermanJ. A.StroupT. S.McEvoyJ. P.SwartzM. S.RosenheckR. A.PerkinsD. O.. . . HsiaoJ. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.
41.
McLeodJ. (2011). Qualitative research in counselling and psychotherapy (2nd ed.). London: Sage.
42.
MitchellA. J.SelmesT. (2007). Why don’t patients take their medicine? Reasons and solutions in psychiatry. Advances in Psychiatric Treatment, 13, 336–346.
43.
MoilanenJ.HaapeaH.MiettunenJ.JaaskelainenE.VeijolaJ.IsohanniM.KoponenH. (2013). Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication—A 10-year follow-up of the Northern Finland 1966 Birth Cohort Study. European Psychiatry, 28, 53–58.
44.
MoisanJ.GrégoireJ. P. (2010). Patterns of discontinuation of atypical antipsychotics in the province of Quebec: A retrospective prescription claims database analysis. Clinical Therapy, 32, 21–31.
45.
MoncrieffJ. (2006). Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica, 114, 3–13.
46.
MoncrieffJ.CohenD. (2005). Rethinking models of psychotropic drug action. Psychotherapy and Psychosomatics, 74, 145–153.
47.
MoncrieffJ.LeoJ. (2010). A systematic review of the effects of antipsychotic drugs on brain volume. Psychological Medicine, 40, 1409–1422.
48.
MorrisonA. P.HuttonP.ShiersD.TurkingtonD. (2012). Antipsychotics: Is it time to introduce patient choice?The British Journal of Psychiatry, 201, 83–84.
49.
MorrisonA. P.HuttonP.WardleM.SpencerH.BarrattS.BrabbanA.. . . TurkingtonD. (2011). Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: An exploratory trial. Psychological Medicine, 42, 1049–1056.
50.
MullinsC. D.ObeidatN. A.CuffelB. J.NaradzayJ.LoebelA. D. (2008). Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophrenia Research, 98(1–3), 8–15.
National Institute for Health and Care Excellence. (2014). Psychosis and schizophrenia in adults: Treatment and management (Clinical Guideline No. 178). London: Author. Available from www.nice.org.uk
53.
National Institute for Health and Clinical Excellence. (2009). Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence (Clinical Guideline No. 76). London: Author. Available from www.nice.org.uk
54.
National Institute for Mental Health in England National Workforce Programme. (2008). Medicines management: Everybody’s business. A guide for service users, carers, and health and social care practitioners. London: Department of Health.
55.
NewcomerJ. W. (2007). Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. Journal of Clinical Psychiatry, 68, 20–27.
56.
O’ConnorA. M.RostomA.FisetV.TetroeJ.EntwhistleV.Llewellyn-ThomasH.. . . JonesJ. (1999). Decision aids for patients facing health treatment or screening decisions: Systematic review. British Medical Journal, 319, 731–734.
57.
OlofinjanaB.TaylorD. (2005). Antipsychotic drugs—information and choice: A patient survey. Psychiatric Bulletin, 29, 369–371.
58.
PilgrimD. (2008). Recovery and current mental health policy. Chronic Illness, 4, 295–304.
59.
PoundP.BrittenN.MorganM.YardleyL.PopeC.Daker-WhiteG.CampbellR. (2005). Resisting medicines: A synthesis of qualitative studies of medicine taking. Social Science & Medicine, 61, 133–155.
60.
ReadJ. (2005). Coping with coming off: Mind’s research into the experience of people trying to come off psychiatric drugs. Leeds, UK: Mind Publications.
61.
RoeD.GoldblattH. (2009). Why and how people decide to stop taking prescribed psychiatric medication: Exploring the subjective process of choice. Psychiatric Rehabilitation Journal, 33, 38–46.
62.
RofailD.HeelisR.GournayK. (2009). Results of a thematic analysis to explore the experiences of patients with schizophrenia taking antipsychotic medication. Clinical Therapeutics, 31, 1488–1496.
63.
ShepherdG.BoardmanJ.SladeM. (2008). Making recovery a reality. London: Sainsbury Centre for Mental Health.
64.
TickleA.BrownD.HaywardM. (2014). Can we risk recovery? A grounded theory of clinical psychologists’ perceptions of risk and recovery-oriented mental health services. Psychology and Psychotherapy: Theory, Research and Practice, 87, 96–110.
65.
TranterR.HealyD. (1998). Neuroleptic discontinuation syndromes. Journal of Psychopharmacology, 12, 401–406.
66.
UsherK. (2001). Taking neuroleptic medicines as the treatment for schizophrenia: A phenomenological study. Australian and New Zealand Journal of Mental Health Nursing, 19, 145–155.
67.
WeidenP. J. (2006). Discontinuing and switching antipsychotic medications: Understanding the CATIE schizophrenia trial. Journal of Clinical Psychiatry, 68, 12–19.
68.
WeinmannS.AderholdV. (2010). Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. Psychosis: Psychological, Social and Integrative Approaches, 2, 50–69.
69.
WhitakerR. (2004). The case against antipsychotic drugs: A 50-year record of doing more harm than good. Medical Hypotheses, 62, 5–13.
70.
WiesjahnM.JungE.LamsterF.RiefW.LincolnT. M. (2014). Explaining attitudes and adherence to antipsychotic medication: The development of a process model. Schizophrenia Research and Treatment, 2014, 1–11.
71.
WilliamsK.PinfoldV. (2006). Side effects: Mental health service users’ experiences of the side effects of anti-psychotic medication. London: Rethink Publications.
72.
WunderinkL.NieboerR. M.WiersmaD.SytemaS.NienhuisS. J. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. The Journal of the American Medical Association Psychiatry, 70, 913–920.
73.
YilmazZ.ZaiC. C.HwangR.MannS.ArenovichT.RemingtonG.DaskalakisZ. J. (2012). Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: A meta-analysis. Schizophrenia Research, 140, 214–220.
74.
YinR. K. (2003). Case study research: Design and methods (3rd ed.). London: Sage.
75.
ZipurskyR. B.MenezesN. M.StreinerD. L. (2014). Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review. Schizophrenia Research, 152, 408–414.
